The board of directors of Viva Biotech Holdings announced that Mr. XIONG Wei (Mr. Xiong) has been appointed as the co-chief financial officer of the group with effect from December 1, 2023 and in such role, he will be reporting to Mr. Mao. Mr. Xiong will be responsible for jointing leading the Group's financial management and capital market related affairs along with Mr. WANG Zheren (Mr. Wang), the Group's current Chief Financial Officer. Mr. Xiong will be primarily focused on the financial management of the Group's contract design and manufacturing (CDMO) and commercialization services while Mr. Wang will be primarily focused on the financial management of the Group's CRO and drug discovery services.

Mr. Xiong, aged 40, joined its Group in November 2020 as part of the Group's acquisition of Zhejiang Langhua Pharmaceutical Co. Ltd., he currently serves as the financial director of Langhua Pharmaceutical and is primarily responsible for its financial management. Mr. Xiong joined Langhua Pharmaceutical in September 2018.

Prior to that, Mr. Xiong was employed by Donghaixiang Group Co. Ltd. from November 2011 to September 2018 where he last served as the executive vice general manager and financial director. He was employed by Zhejiang Yongtai Technology Co.

Ltd. from May 2007 to November 2011 where he last served as the investment director and securities business representatives and by CITIC Securities where he last served as an industry analyst from July 2005 to November 2006. Mr. Xiong graduated from the Huazhong University of Science and Technology School of Economics with a degree in international economics and trade and from the Zhongnan University of Economics and Law with a degree in law in June 2005. He is qualified to serve as a board secretary for companies listed on the Shanghai Stock Exchange and Shenzhen Stock Exchange, and has been qualified as a senior economist since November 2023.